MIRA Pharmaceuticals (MIRA) Expected to Announce Quarterly Earnings on Friday

MIRA Pharmaceuticals (NASDAQ:MIRA) is expected to issue its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter.

MIRA Pharmaceuticals Trading Up 6.7%

Shares of NASDAQ:MIRA opened at $1.12 on Thursday. The firm has a market cap of $46.91 million, a price-to-earnings ratio of -0.73 and a beta of 1.78. The stock’s 50-day moving average price is $1.23 and its two-hundred day moving average price is $1.38. MIRA Pharmaceuticals has a 12-month low of $0.73 and a 12-month high of $2.45.

Hedge Funds Weigh In On MIRA Pharmaceuticals

Large investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of MIRA Pharmaceuticals in the 2nd quarter valued at about $26,000. Creative Planning purchased a new position in MIRA Pharmaceuticals in the second quarter valued at approximately $27,000. Two Sigma Investments LP raised its holdings in MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after buying an additional 25,816 shares during the period. Finally, Geode Capital Management LLC lifted its position in MIRA Pharmaceuticals by 100.0% during the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after buying an additional 136,438 shares in the last quarter. 35.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MIRA has been the topic of several research analyst reports. Rodman & Renshaw assumed coverage on shares of MIRA Pharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.